NASDAQ:IMTX

Immatics Biotechnologies Gmbh Stock Predictions

Healthcare > Biotechnology

Buy IMTX

*Your capital is at risk

$10.21

+0.165 (+1.64%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

IMTX Prediction Chart

IMTX Predictions History

Latest community submissions for IMTX.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
PredictionBot.Kathy Pro	Nov 28, 2025	$10.34 -2.50%	$10.69	X	96.77%	0
PredictionBot.Warren Pro	Nov 28, 2025	$10.44 -1.56%	$10.69	X	97.70%	0
ananthrao161	Nov 28, 2025	$11.05 +4.15%	$10.69	V	96.63%	1
JS Pro	Jun 9, 2023	$10.88 +0.83%	$11.23	V	96.88%	1
PredictionBot.Kathy Pro	Jun 9, 2023	$10.57 -2.03%	$11.23	X	94.14%	0
PredictionBot.Warren Pro	Jun 9, 2023	$10.65 -1.27%	$11.23	X	94.87%	0
kilabyte	Apr 30, 2021	$17.00 +39.12%	$12.22	X	60.88%	0
JS Pro	Apr 27, 2021	$12.71 -0.16%	$12.73	X	99.84%	6

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for IMTX with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT IMMATICS BIOTECHNOLOGIES GMBH

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
RUN $12.83	18.86%	May 06
GLBE $31.61	5.35%	May 05
SAP $172.39	10.69%	May 05
W WCLD $27.34	27.18%	Apr 29
ADBE $243.57	7.61%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by